IP Library Patent Application 17400660
Patent Application
App. No. 17/400,660

MIRNAS AS BIOMAKERS FOR DISTINGUISHING BENIGN FROM MALIGNANT THYROID NEOPLASMS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/400,660
Abstract

The present invention concerns methods and compositions for identifying a miRNA profile for a particular condition, such as thyroid nodules or thyroid cancer, and using the profile in the diagnosis of a patient for a condition, such as thyroid nodules or thyroid cancer.

Claims (20)

1 - 34 . (canceled)

35 . A method of producing a thyroid miRNA profile, the method comprising

sequencing a population of miRNAs from a thyroid sample from a subject, wherein the sequencing comprises contacting the thyroid sample from the subject with labeled primers specific for a group of microRNAs comprising miR-375, miR-146b-5p, mir-138-1*, and miR-204;

detecting the sequences of the miRNAs of miR-375, miR-146b-5p, mir-138-1*, and miR-204; and

analyzing the detected detecting the sequences of the miRNAs of miR-375, miR-146b-5p, mir-138-1*, and miR-204 to produce the thyroid miRNA profile.

36 . The method of claim 35 , wherein the method further comprises measuring expression levels of microRNAs miR-375, miR-146b-5p, mir-138-1*, and miR-204 from the thyroid sample from the subject with the labeled modified nucleotide microRNA probes that bind specifically to miR-375, miR-146b-5p, mir-138-1*, and miR-204 to produce the thyroid microRNA profile.

37 . A method of treating a subject identified with a papillary thyroid carcinoma, the method comprising:

contacting the thyroid sample from the subject with labeled primers specific for a group of microRNAs comprising miR-375, miR-146b-5p, mir-138-1*, and miR-204; and

reacting the sample with the labeled primers under conditions to amplify the microRNAs using polymerase chain reaction to produce the labeled nucleotide sequences;

measuring expression levels of microRNAs miR-375, miR-146b-5p, mir-138-1*, and miR-204 from the unclassified thyroid sample from the subject with the labeled modified nucleotide microRNA probes that bind specifically to miR-375, miR-146b-5p, mir-138-1*, and miR-204 to produce a microRNA profile based upon the binding of the labeled nucleotide microRNA probes and the labeled nucleotide sequences produced using the polymerase chain reaction;

comparing the expression levels of the microRNAs in the profile from the unclassified thyroid sample from the subject to a normal thyroid reference level for each miRNA;

identifying the unclassified thyroid sample as papillary thyroid carcinoma when the profile expression levels of miR-375, miR-146b-5p are increased as compared to the normal reference level and mir-138-1* and miR-204 are decreased as compared to the normal reference level; and

treating the subject whose sample was identified as papillary thyroid carcinoma.

38 . The method of claim 37 , wherein the treating comprises administering radioactive iodine, radiation, or chemotherapy to the subject identified as having papillary thyroid carcinoma or performing a thyroidectomy on the subject identified as having papillary thyroid carcinoma.

39 . A composition comprising labeled thyroid derived nucleic acid molecules, wherein the labeled molecules comprise nucleic acid molecules that hybridize with or correspond to miR-375, miR-146b-5p, mir-138-1*, and miR-204.

40 . The composition of claim 39 , wherein the label is non-radioactive.

41 . The composition of claim 39 , wherein the label is radioactive.

42 . The composition of claim 39 , wherein the label is a UV spectrum emitting label.

43 . The composition of claim 39 , wherein the label is a fluorescent label.

44 . The composition of claim 39 , wherein the label is an enzymatic label.

Assignments (3)
SECURITY INTEREST Recorded Nov 2, 2021
From: INTERPACE BIOSCIENCES, INC.; INTERPACE DIAGNOSTICS CORPORATION; INTERPACE DIAGNOSTICS, LLC; INTERPACE PHARMA SOLUTIONS, INC.
To: BROADOAK FUND V, L.P.
Reel/Frame 057988/0110 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 16, 2021
From: ASURAGEN, INC.
To: INTERPACE DIAGNOSTICS, LLC
Reel/Frame 057189/0256 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 16, 2021
From: BEAUDENON-HUIBREGTSE, SYLVIE; CHOUDHARY, ASHISH
To: ASURAGEN, INC.
Reel/Frame 057629/0771 →